The impact of recombinant parathyroid hormone on malignancies and mortality: 7 Years of experience based on nationwide Danish registers

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 639-644

  Bang, U C ^a   Hyldstrup, L ^a,b   Jensen, J E B ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Cohort study; Mortality; Osteoporosis; Parathyroid hormone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; BONE DENSITY CONSERVATION AGENT; PARATHYROID HORMONE; RECOMBINANT PROTEIN;

AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ICD-10; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOPOROSIS; OSTEOSARCOMA; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINE FRACTURE; CHEMICALLY INDUCED; DENMARK; EPIDEMIOLOGY; LUNG TUMOR; MIDDLE AGED; MORTALITY; NEOPLASM; REGISTER; SEX DIFFERENCE;

AGED; BONE DENSITY CONSERVATION AGENTS; DENMARK; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OSTEOPOROSIS; PARATHYROID HORMONE; RECOMBINANT PROTEINS; REGISTRIES; SEX FACTORS;

EID: 84899096982     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2470-y     Document Type: Article

References (27)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
2. Tashjian AH Jr, Gagel RF (2006) Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365
3. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321 (Pubitemid 34556102)
4. Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929-940 (Pubitemid 46011145)
5. Cipriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27:2419-2428
6. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041-1045
7. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429-2437
8. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30-33
9. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38-41
10. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53:441-449 (Pubitemid 44816920)
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383 (Pubitemid 17055592)
12. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340-1344 (Pubitemid 10124272)
13. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 127:2159-2168
14. Fedirko V, Riboli E, Bueno-de-Mesquita HB, Rinaldi S, Pischon T, Norat T, Jansen EH, van Duijnhoven FJ, Tjonneland A, Olsen A, Overvad K, Boutron-RuaultMC, Clavel-Chapelon F, Engel P, Kaaks R, Teucher B, Boeing H, Buijsse B, Trichopoulou A, Trichopoulos D, Lagiou P, Sieri S, Vineis P, Panico S, Palli D, Tumino R, van Gils CH, Peeters PH, Chirlaque MD, Gurrea AB, Rodriguez L, Molina-Montes E, Dorronsoro M, Bonet C, Palmqvist R, Hallmans G, Key TJ, Tsilidis KK, Khaw KT, Romieu I, Straif K, Wark PA, Romaguera D, Jenab M (2011) Prediagnostic circulating parathyroid hormone concentration and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Epidemiol Biomark Prev 20:767-778
15. Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23:1377-1385
16. Nilsson IL, Zedenius J, Yin L, Ekbom A (2007) The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14:135-140 (Pubitemid 47521729)
17. Pickard AL, Gridley G, Mellemkjae L, Johansen C, Kofoed-Enevoldsen A, Cantor KP, Brinton LA (2002) Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 95:1611-1617
18. Aslan D, Andersen MD, Gede LB, de Franca TK, Jorgensen SR, Schwarz P, Jorgensen NR (2012) Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 72:14-22
19. Powell HA, Iyen-Omofoman B, Baldwin DR, Hubbard RB, Tata LJ (2012) Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis. J Thorac Oncol
20. Michels KB, Xue F, Brandt L, Ekbom A (2004) Hyperparathyroidism and subsequent incidence of breast cancer. Int J Cancer 110:449-451 (Pubitemid 38649899)
21. Ji J, Sundquist K, Sundquist J (2012) Cancer risk after hospitalization for osteoporosis in Sweden. Eur J Cancer Prev 21:395-399
22. McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH (2008) Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer 122:1879-1884 (Pubitemid 351413438)
23. Lahat G, LazarA, Lev D (2008) Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am 88:451-481, v (Pubitemid 351734513)
24. Lau E, Ong K, Kurtz S, Schmier J, Edidin A (2008) Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am 90:1479-1486 (Pubitemid 351947589)
25. Gonzalez-Calvin JL, Garcia-Sanchez A, Bellot V, Munoz-Torres M, Raya-Alvarez E, Salvatierra-Rios D (1993) Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcohol 28:571-579 (Pubitemid 23316910)
26. Kanis JA, Johnell O, Oden A, Johansson H, De LC, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155-162 (Pubitemid 40193202)
27. Wiklund P, Nordstrom A, Jansson JH, Weinehall L, Nordstrom P (2012) Low bonemineral density is associated with increased risk for myocardial infarction in men and women. Osteoporos Int 23:963-970